secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alaunos Therapeutics, Inc. (TCRT)
CIK:        0001107421
Form:       8-K
Filed at:   2026-10-13T13:28:22+00:00
Accession:  0001193125-26-419829
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 5.03, 2.01, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Alaunos acquires Velaris; PIPE raises ~$350M; board and charter overhaul set for vote
--------------------------------------------------------------------------------

- Alaunos acquired Velaris on Oct. 13, 2026; issued Velaris holders 105,286 Series B and 33,054 Series C preferred shares, each convertible into 1,000 common shares.
- PIPE financing: 687,789 common at $1.4357 and 243,063 Series C at $1,435.70 for ~$350M; closing expected Oct. 14, 2026; proceeds to fund Velaris programs and working capital.
- Peter Harwin appointed director; Postma, Jerman and Vieser resign upon stockholder approval of conversion proposal; Lead Investor designees to hold 4 of 5 board seats.
- Meeting proposals include conversion of Series B/C preferred, name change to Velaris Therapeutics, reverse stock split, authorized share increase and redomestication.
- Velaris signed ADOA with Paragon for Fc fusion protein programs (ActRIIA/ActRIIB, BMP9/10-sparing ActRIIA); Paragon gets two warrants each for 1% of fully diluted shares, first 120 days post-close.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1107421/000119312526419829/0001193125-26-419829-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1107421/000119312526419829/tcrt-20261013.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-419829

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer